OmniAb, Inc. Common Stock
OABIStock
$2.04+4.39%52W
Market Cap$310.24M
P/E—
Div yield—
Beta0.44
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)7.63%
Price vs S&P 500 (4W)1.82%
VGM Score52.62
Market Capitalization$310.24M
Earnings Surprise History
Q1 26-0.06est. -0.10
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.23
4.23
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OABIOmniAb, Inc. Common Stock | D | C | B | $2.04 |
| IQVIQVIA Holdings Inc. | C | C | B | $210.49 |
| INCYIncyte Genomics Inc | C | A | B | $116.65 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | $537.92 |
| ICLRIcon Plc | C | C | B | $170.00 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $229.16 |
| ABSIAbsci Corporation Common Stock | F | F | A | $8.23 |
| NRCNRC Health Common Stock | D | D | B | $21.94 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | $1.35 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.69 |
| BIAFbioAffinity Technologies, Inc. Common Stock | A | F | F | $0.71 |
About
OmniAb licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses engineered transgenic animals powered by proprietary Biological Intelligence to rapidly identify optimized antibody candidates for drug development. The company generates revenue through licensing agreements that accelerate its partners' therapeutic discovery efforts.